Enzo Biochem (ENZ) 3.12 $ENZ
Enzo Biochem Announces New Molecular Platform and First Product for Early Focus on Cervical Cancer Progression
Business Wire - Tue Feb 10, 9:00AM CST
Enzo Biochem, Inc. (NYSE:ENZ) today announced the development of a new novel platform with consequential and broad application for detection of genotypic and phenotypic markers via flow cytometry, as well as the first product for its use addressing the cervical cancer testing market.
ENZ: 3.12 (-0.18)
In Case You Missed it, This New Cancer Study is Terrifying
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 10, 8:12AM CST
Source: Flickr user Erik Soderstrom. Cancer is possibly the scariest diagnosis a patient can be given. Within the United States cancer is the second-leading cause of death behind only heart disease. It was responsible for nearly 577,000 deaths in...
MYGN: 34.03 (+0.40), ENZ: 3.12 (-0.18), EXAS: 25.56 (-0.54)
Enzo Biochem's (ENZ) Management on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Dec 10, 12:13PM CST
ENZ: 3.12 (-0.18)
Enzo Biochem ups revenues 3% in FQ1
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 6:35AM CST
ENZ: 3.12 (-0.18)
Enzo Biochem EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 3:59PM CST
ENZ: 3.12 (-0.18)
Enzo Biochem reports 1Q loss
Automated Insights - Tue Dec 09, 3:21PM CST
FARMINGDALE, N.Y. (AP) _ Enzo Biochem Inc. (ENZ) on Tuesday reported a loss of $3.7 million, or 8 cents per share, in its fiscal first quarter.
ENZ: 3.12 (-0.18)
Enzo Biochem Reports Strong Fiscal First Quarter Results
Business Wire - Tue Dec 09, 3:15PM CST
Enzo Biochem, Inc. (NYSE: ENZ) today reported strong operating results for the fiscal first quarter ended October 31, 2014.
ENZ: 3.12 (-0.18)
Enzo reports December 10
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 3:30PM CST
ENZ: 3.12 (-0.18)
Enzo Biochem Schedules Teleconference to Discuss First Quarter Results Wednesday, December 10, 2014 at 8:30 AM E.T.
Business Wire - Wed Dec 03, 9:00AM CST
Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2015 first quarter results, Wednesday, December 10, 2014, at 8:30 AM E.T.
ENZ: 3.12 (-0.18)
2014-2014 UK Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
M2 - Mon Nov 24, 10:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/swvhm8/20142014_uk) has announced the addition of the "2014-2014 UK Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures" report to their offering. The report presents a detailed analysis of the Hepatitis diagnostics market in the UK. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the following markets: - Hospitals - Commercial/Private Labs - Blood Banks In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns. Key Topics Covered: - INTRODUCTION - HEPATITIS WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW - UK: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND MARKET SHARES - POTENTIAL MARKET ENTRY BARRIERS AND RISKS - COMPETITIVE ASSESSMENTS - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - Bio-Rad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Enzo Biochem - Fujirebio/Innogenetics - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech - Life Technology - Lonza - Nanogen/Elitech - Novartis Diagnostics/Grifols - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/sw...0142014_uk
SQNM: 3.62 (unch), ENZ: 3.12 (-0.18), CPHD: 59.62 (+0.72), DHR: 86.81 (+0.21), HOLX: 30.46 (+0.21), NVS: 102.20 (-0.17)
Enzo Biochem (ENZ) in Focus: Stock Moves 6.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 8:25AM CST
Enzo Biochem (ENZ) was a big mover last session, with shares rising nearly 7% on the day.
BIIB: 391.66 (-0.45), ENZ: 3.12 (-0.18), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:57AM CDT
Enzo Biochem stock could bring additional losses for your portfolio
HALO: 14.73 (+0.23), EBS: 28.76 (-0.12), ENZ: 3.12 (-0.18), EPZM: 21.58 (+0.08)
Enzo Biochem Reports Strong Fiscal Fourth Quarter Results
Business Wire - Thu Oct 09, 3:15PM CDT
Enzo Biochem Inc. (NYSE:ENZ) today reported results for the fourth quarter and fiscal year ended July 31, 2014, with continued solid year-end gains posted by both Life Sciences and Clinical Labs.
ENZ: 3.12 (-0.18)
Enzo Biochem wins novel vectors patent for gene therapy treatments in the US
M2 - Wed Oct 08, 7:58AM CDT
Molecular diagnostics company Enzo Biochem (NYSE:ENZ) reported on Tuesday the receipt of the patent for novel vectors for gene therapy treatments for cancers, virus infections and genetic diseases in the US.
ENZ: 3.12 (-0.18)
Enzo Biochem Awarded Patent for Novel Vectors Involving Gene Therapy Treatments for Cancer, Virus Infections and Genetic Diseases
Business Wire - Tue Oct 07, 8:02AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today announced that the U.S. Patent and Trademark Office has awarded the Company Patent No. 8,846,893, covering novel vectors for gene therapy treatments for cancers, virus infections and genetic diseases.
ENZ: 3.12 (-0.18)
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter Results Friday, October 10, 2014 at 8:30 AM E.T.
Business Wire - Mon Oct 06, 9:00AM CDT
Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2014 fourth quarter results, Friday, October 10, 2014, at 8:30 AM E.T.
ENZ: 3.12 (-0.18)
UK Major Infectious Disease Testing Product Suppliers by Assay and Country 2014
M2 - Thu Oct 02, 5:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjvfjn/uk_sales_and) has announced the addition of the "UK Sales and Market Shares of Major Infectious Disease Testing Product Suppliers by Assay and Country" report to their offering. This unique report provides UK sales and market share estimates for major suppliers of infectious disease testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. List of Tables - U.K. AIDS Testing Market Diagnostics Sales by Major Supplier - U.K. Campylobacter Testing Market Diagnostics Sales by Major Supplier - U.K. Candida Testing Market Diagnostics Sales by Major Supplier - U.K. Gonorrhea Testing Market Diagnostics Sales by Major Supplier - U.K. Hepatitis Testing Market Diagnostics Sales by Major Supplier - U.K. Hepatitis C Testing Market Diagnostics Sales by Major Supplier - U.K. Influenza Testing Market Diagnostics Sales by Major Supplier - U.K. Mycoplasma Testing Market Diagnostics Sales by Major Supplier - U.K. Pneumonia Testing Market Diagnostics Sales by Major Supplier - U.K. RSV Testing Market Diagnostics Sales by Major Supplier - U.K. Rubella Testing Market Diagnostics Sales by Major Supplier - U.K. Septicemia Testing Market Diagnostics Sales by Major Supplier - U.K. Shigella Testing Market Diagnostics Sales by Major Supplier - U.K. Streptococci Testing Market Diagnostics Sales by Major Supplier - U.K. Syphilis Testing Market Diagnostics Sales by Major Supplier - U.K. Tuberculosis Testing Market Diagnostics Sales by Major Supplier Competitive Assessments - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - Biomerieux - Bio-Rad - Cepheid - Diamedix - Diasorin - Eiken Chemical - Enzo Biochem - Fujirebio/Innogenetics - Grifols/Novartis Diagnostics - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech - Lonza - Nanogen/Elitech - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - ThermoFisher/Life Technologies - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/rj..._sales_and
SQNM: 3.62 (unch), ENZ: 3.12 (-0.18), CPHD: 59.62 (+0.72), DHR: 86.81 (+0.21), HOLX: 30.46 (+0.21), NVS: 102.20 (-0.17)
2014 UK Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country
M2 - Thu Oct 02, 5:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjh39d/uk_sales_and) has announced the addition of the "UK Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country" report to their offering. This unique report provides UK sales and market share estimates for major suppliers of cancer diagnostic testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. List of Tables - U.K., Total Tumor Marker Sales by Major Supplier - U.K., CEA Testing Market Diagnostics - Sales by Major Supplier - U.K., PSA Testing Market Diagnostics - Sales by Major Supplier Companies Mentioned: - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Quest Diagnostics - Radient Pharmaceuticals - Roche - Siemens Healthcare - Takara Bio - Thermo Fisher/Life Technologies - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/vj..._sales_and
ENZ: 3.12 (-0.18), A: 40.15 (+0.13), DGX: 71.68 (+0.03), DHR: 86.81 (+0.21)
US Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country
M2 - Tue Sep 30, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nqkj8f/us_sales_and) has announced the addition of the "US Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country" report to their offering. This unique report provides US sales and market share estimates for major suppliers of cancer diagnostic testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Companies Mentioned: Partial List - Diagnocure - Diasorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio For more information visit http://www.researchandmarkets.com/research/nq..._sales_and
SQNM: 3.62 (unch), MYGN: 34.03 (+0.40), ENZ: 3.12 (-0.18), DGX: 71.68 (+0.03), HOLX: 30.46 (+0.21)
Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country
M2 - Tue Sep 30, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwszsk/sales_and_market) has announced the addition of the "Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country" report to their offering. This new report provides sales and market share estimates for major suppliers of cancer diagnostic testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Companies Featured (Partial List) - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - DiaSorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech For more information visit http://www.researchandmarkets.com/research/mw...and_market
MYGN: 34.03 (+0.40), ENZ: 3.12 (-0.18), A: 40.15 (+0.13), CPHD: 59.62 (+0.72), DHR: 86.81 (+0.21), HOLX: 30.46 (+0.21)
Enzo Biochem Announces New Molecular Platform and First Product for Early Focus on Cervical Cancer Progression
Business Wire - Tue Feb 10, 9:00AM CST
Enzo Biochem, Inc. (NYSE:ENZ) today announced the development of a new novel platform with consequential and broad application for detection of genotypic and phenotypic markers via flow cytometry, as well as the first product for its use addressing the cervical cancer testing market.
ENZ: 3.12 (-0.18)
In Case You Missed it, This New Cancer Study is Terrifying
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 10, 8:12AM CST
Source: Flickr user Erik Soderstrom. Cancer is possibly the scariest diagnosis a patient can be given. Within the United States cancer is the second-leading cause of death behind only heart disease. It was responsible for nearly 577,000 deaths in...
MYGN: 34.03 (+0.40), ENZ: 3.12 (-0.18), EXAS: 25.56 (-0.54)
Enzo Biochem's (ENZ) Management on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Dec 10, 12:13PM CST
ENZ: 3.12 (-0.18)
Enzo Biochem ups revenues 3% in FQ1
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 6:35AM CST
ENZ: 3.12 (-0.18)
Enzo Biochem EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 3:59PM CST
ENZ: 3.12 (-0.18)
Enzo Biochem reports 1Q loss
Automated Insights - Tue Dec 09, 3:21PM CST
FARMINGDALE, N.Y. (AP) _ Enzo Biochem Inc. (ENZ) on Tuesday reported a loss of $3.7 million, or 8 cents per share, in its fiscal first quarter.
ENZ: 3.12 (-0.18)
Enzo Biochem Reports Strong Fiscal First Quarter Results
Business Wire - Tue Dec 09, 3:15PM CST
Enzo Biochem, Inc. (NYSE: ENZ) today reported strong operating results for the fiscal first quarter ended October 31, 2014.
ENZ: 3.12 (-0.18)
Enzo reports December 10
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 3:30PM CST
ENZ: 3.12 (-0.18)
Enzo Biochem Schedules Teleconference to Discuss First Quarter Results Wednesday, December 10, 2014 at 8:30 AM E.T.
Business Wire - Wed Dec 03, 9:00AM CST
Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2015 first quarter results, Wednesday, December 10, 2014, at 8:30 AM E.T.
ENZ: 3.12 (-0.18)
2014-2014 UK Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
M2 - Mon Nov 24, 10:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/swvhm8/20142014_uk) has announced the addition of the "2014-2014 UK Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures" report to their offering. The report presents a detailed analysis of the Hepatitis diagnostics market in the UK. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the following markets: - Hospitals - Commercial/Private Labs - Blood Banks In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns. Key Topics Covered: - INTRODUCTION - HEPATITIS WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW - UK: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND MARKET SHARES - POTENTIAL MARKET ENTRY BARRIERS AND RISKS - COMPETITIVE ASSESSMENTS - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - Bio-Rad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Enzo Biochem - Fujirebio/Innogenetics - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech - Life Technology - Lonza - Nanogen/Elitech - Novartis Diagnostics/Grifols - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/sw...0142014_uk
SQNM: 3.62 (unch), ENZ: 3.12 (-0.18), CPHD: 59.62 (+0.72), DHR: 86.81 (+0.21), HOLX: 30.46 (+0.21), NVS: 102.20 (-0.17)
Enzo Biochem (ENZ) in Focus: Stock Moves 6.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 8:25AM CST
Enzo Biochem (ENZ) was a big mover last session, with shares rising nearly 7% on the day.
BIIB: 391.66 (-0.45), ENZ: 3.12 (-0.18), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:57AM CDT
Enzo Biochem stock could bring additional losses for your portfolio
HALO: 14.73 (+0.23), EBS: 28.76 (-0.12), ENZ: 3.12 (-0.18), EPZM: 21.58 (+0.08)
Enzo Biochem Reports Strong Fiscal Fourth Quarter Results
Business Wire - Thu Oct 09, 3:15PM CDT
Enzo Biochem Inc. (NYSE:ENZ) today reported results for the fourth quarter and fiscal year ended July 31, 2014, with continued solid year-end gains posted by both Life Sciences and Clinical Labs.
ENZ: 3.12 (-0.18)
Enzo Biochem wins novel vectors patent for gene therapy treatments in the US
M2 - Wed Oct 08, 7:58AM CDT
Molecular diagnostics company Enzo Biochem (NYSE:ENZ) reported on Tuesday the receipt of the patent for novel vectors for gene therapy treatments for cancers, virus infections and genetic diseases in the US.
ENZ: 3.12 (-0.18)
Enzo Biochem Awarded Patent for Novel Vectors Involving Gene Therapy Treatments for Cancer, Virus Infections and Genetic Diseases
Business Wire - Tue Oct 07, 8:02AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today announced that the U.S. Patent and Trademark Office has awarded the Company Patent No. 8,846,893, covering novel vectors for gene therapy treatments for cancers, virus infections and genetic diseases.
ENZ: 3.12 (-0.18)
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter Results Friday, October 10, 2014 at 8:30 AM E.T.
Business Wire - Mon Oct 06, 9:00AM CDT
Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2014 fourth quarter results, Friday, October 10, 2014, at 8:30 AM E.T.
ENZ: 3.12 (-0.18)
UK Major Infectious Disease Testing Product Suppliers by Assay and Country 2014
M2 - Thu Oct 02, 5:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjvfjn/uk_sales_and) has announced the addition of the "UK Sales and Market Shares of Major Infectious Disease Testing Product Suppliers by Assay and Country" report to their offering. This unique report provides UK sales and market share estimates for major suppliers of infectious disease testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. List of Tables - U.K. AIDS Testing Market Diagnostics Sales by Major Supplier - U.K. Campylobacter Testing Market Diagnostics Sales by Major Supplier - U.K. Candida Testing Market Diagnostics Sales by Major Supplier - U.K. Gonorrhea Testing Market Diagnostics Sales by Major Supplier - U.K. Hepatitis Testing Market Diagnostics Sales by Major Supplier - U.K. Hepatitis C Testing Market Diagnostics Sales by Major Supplier - U.K. Influenza Testing Market Diagnostics Sales by Major Supplier - U.K. Mycoplasma Testing Market Diagnostics Sales by Major Supplier - U.K. Pneumonia Testing Market Diagnostics Sales by Major Supplier - U.K. RSV Testing Market Diagnostics Sales by Major Supplier - U.K. Rubella Testing Market Diagnostics Sales by Major Supplier - U.K. Septicemia Testing Market Diagnostics Sales by Major Supplier - U.K. Shigella Testing Market Diagnostics Sales by Major Supplier - U.K. Streptococci Testing Market Diagnostics Sales by Major Supplier - U.K. Syphilis Testing Market Diagnostics Sales by Major Supplier - U.K. Tuberculosis Testing Market Diagnostics Sales by Major Supplier Competitive Assessments - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - Biomerieux - Bio-Rad - Cepheid - Diamedix - Diasorin - Eiken Chemical - Enzo Biochem - Fujirebio/Innogenetics - Grifols/Novartis Diagnostics - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech - Lonza - Nanogen/Elitech - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - ThermoFisher/Life Technologies - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/rj..._sales_and
SQNM: 3.62 (unch), ENZ: 3.12 (-0.18), CPHD: 59.62 (+0.72), DHR: 86.81 (+0.21), HOLX: 30.46 (+0.21), NVS: 102.20 (-0.17)
2014 UK Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country
M2 - Thu Oct 02, 5:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjh39d/uk_sales_and) has announced the addition of the "UK Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country" report to their offering. This unique report provides UK sales and market share estimates for major suppliers of cancer diagnostic testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. List of Tables - U.K., Total Tumor Marker Sales by Major Supplier - U.K., CEA Testing Market Diagnostics - Sales by Major Supplier - U.K., PSA Testing Market Diagnostics - Sales by Major Supplier Companies Mentioned: - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Quest Diagnostics - Radient Pharmaceuticals - Roche - Siemens Healthcare - Takara Bio - Thermo Fisher/Life Technologies - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/vj..._sales_and
ENZ: 3.12 (-0.18), A: 40.15 (+0.13), DGX: 71.68 (+0.03), DHR: 86.81 (+0.21)
US Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country
M2 - Tue Sep 30, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nqkj8f/us_sales_and) has announced the addition of the "US Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country" report to their offering. This unique report provides US sales and market share estimates for major suppliers of cancer diagnostic testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Companies Mentioned: Partial List - Diagnocure - Diasorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio For more information visit http://www.researchandmarkets.com/research/nq..._sales_and
SQNM: 3.62 (unch), MYGN: 34.03 (+0.40), ENZ: 3.12 (-0.18), DGX: 71.68 (+0.03), HOLX: 30.46 (+0.21)
Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country
M2 - Tue Sep 30, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwszsk/sales_and_market) has announced the addition of the "Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country" report to their offering. This new report provides sales and market share estimates for major suppliers of cancer diagnostic testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Companies Featured (Partial List) - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - DiaSorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech For more information visit http://www.researchandmarkets.com/research/mw...and_market
MYGN: 34.03 (+0.40), ENZ: 3.12 (-0.18), A: 40.15 (+0.13), CPHD: 59.62 (+0.72), DHR: 86.81 (+0.21), HOLX: 30.46 (+0.21)
